R38
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 85
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.470
- P53_PATHWAY+0.390
- TGF_BETA_SIGNALING+0.390
- UV_RESPONSE_UP+0.380
- TNFA_SIGNALING_VIA_NFKB+0.360
- ESTROGEN_RESPONSE_EARLY+0.350
- HYPOXIA+0.330
- WNT_BETA_CATENIN_SIGNALING+0.320
- MYC_TARGETS_V2+0.280
- ESTROGEN_RESPONSE_LATE+0.270
Top 10 suppressed
- PROTEIN_SECRETION-0.510
- E2F_TARGETS-0.360
- G2M_CHECKPOINT-0.340
- INTERFERON_ALPHA_RESPONSE-0.320
- INTERFERON_GAMMA_RESPONSE-0.230
- KRAS_SIGNALING_UP-0.220
- MITOTIC_SPINDLE-0.160
- ALLOGRAFT_REJECTION-0.140
- MYC_TARGETS_V1-0.140
- UNFOLDED_PROTEIN_RESPONSE-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R168 | — | — | 0.874 |
| 2 | SRR4195649 | — | — | 0.813 |
| 3 | a8235ad1-0c5f-4a0b-b595-85ef3a1e49ff | — | — | 0.803 |
| 4 | a4322796-9189-48c2-9e7c-7b1493b5799a | — | — | 0.803 |
| 5 | SAMN03290915 | — | — | 0.792 |
| 6 | 1e82995c-f318-4225-96d4-f1e98bcbf60b | — | — | 0.776 |
| 7 | 1c3d6580-0dc8-4346-a4f7-0bb404d4a245 | — | — | 0.763 |
| 8 | TCGA-56-5898-01A-11R-1635-07 | — | cohortSQ1 | 0.757 |
| 9 | BS_196BBNEJ | Posterior Fossa Ependymoma | — | 0.755 |
| 10 | 40b92a76-f324-4cdd-8209-517d021acd47 | — | — | 0.755 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.470 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.390 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.380 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.350 | Inavolisib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |